SALAGEN Drug Patent Profile

« Back to Dashboard

When do Salagen patents expire, and what generic alternatives are available?

Salagen is a drug marketed by Advanz Pharma and is included in one NDA.

The generic ingredient in SALAGEN is pilocarpine hydrochloride. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the pilocarpine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Salagen

A generic version of SALAGEN was approved as pilocarpine hydrochloride by INNOGENIX on December 22^nd, 2004.

Summary for SALAGEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	7
Patent Applications:	5,102
Drug Prices:	Drug price information for SALAGEN
What excipients (inactive ingredients) are in SALAGEN?	SALAGEN excipients list
DailyMed Link:	SALAGEN at DailyMed

See drug prices for SALAGEN

Recent Clinical Trials for SALAGEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Pharma Europe B.V.	Phase 1
Federal University of São Paulo	Phase 3
Roxane Laboratories	N/A

See all SALAGEN clinical trials

Pharmacology for SALAGEN

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Agonists Cholinergic Muscarinic Agonists

US Patents and Regulatory Information for SALAGEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Advanz Pharma	SALAGEN	pilocarpine hydrochloride	TABLET;ORAL	020237-001	Mar 22, 1994	AB	RX	Yes	No
Advanz Pharma	SALAGEN	pilocarpine hydrochloride	TABLET;ORAL	020237-002	Apr 18, 2003	AB	RX	Yes	Yes

Salagen Market Dynamics, Financial Trajectory, Patent Status, and Generic Competition

Last updated: October 28, 2026

Salagen, the brand name for pilocarpine hydrochloride tablets, is a mature, largely genericized prescription product used to treat dry mouth caused by radiotherapy for head and neck cancer and symptoms of xerostomia associated with Sjögren's syndrome. The product has no meaningful remaining regulatory exclusivity, faces generic competition, and is unlikely to generate material growth for its marketer. Its commercial value is concentrated in residual brand demand, physician familiarity, insurance coverage, and patients who remain stable on the branded product.

The financial trajectory is therefore structurally defensive rather than growth-oriented. Public company filings generally do not disclose Salagen revenue as a separate line item, preventing a reliable standalone sales estimate. Market economics are driven more by generic supply, reimbursement, shortage risk, and treatment persistence than by new indication expansion.

What is Salagen and who markets pilocarpine tablets?

Salagen contains pilocarpine hydrochloride, a muscarinic cholinergic agonist that stimulates exocrine gland secretion. The FDA-approved tablet strengths are 5 mg and 7.5 mg.

Product attribute	Salagen
Active ingredient	Pilocarpine hydrochloride
Dosage form	Immediate-release oral tablet
Approved strengths	5 mg and 7.5 mg
Primary indications	Radiation-induced xerostomia; Sjögren's syndrome xerostomia
U.S. regulatory application	NDA 020237
Original innovator	MGI Pharma, later acquired by Eisai
Current commercial context	Mature brand with generic competition
Regulatory exclusivity	Expired
Primary substitutes	Generic pilocarpine tablets; cevimeline for some Sjögren's patients

FDA labeling recommends 5 mg four times daily for many patients with Sjögren's syndrome and 5 mg three times daily for radiation-induced xerostomia, with dose adjustment based on tolerability and clinical response. The medicine can cause sweating, nausea, diarrhea, chills, flushing, urinary frequency, and visual effects. These tolerability issues limit the addressable market and create switching opportunities to alternative treatment or supportive care. (FDA, 2021)

Eisai acquired MGI Pharma in 2008. Salagen was part of the acquired commercial portfolio, but Eisai's public financial reporting has not generally broken out Salagen sales as a separately reported product. The absence of product-level disclosure makes historical revenue reconstruction dependent on third-party prescription and market data rather than audited company reporting.

When did Salagen lose exclusivity?

Salagen lost practical market exclusivity years ago. The original product patents and regulatory exclusivity periods expired before the current generic market developed.

The principal U.S. exclusivity events were:

Event	Timing
FDA approval of Salagen tablets	1994
Generic development and ANDA activity	Began after expiration of relevant exclusivity and patent barriers
Current Orange Book exclusivity	None expected
Current brand patent protection	No material blocking protection identified in the public regulatory record
Generic availability	Established

The Orange Book is the controlling FDA source for listed patents, exclusivity, and approved generic equivalents. Salagen's commercial position is consistent with an off-patent small-molecule product: multiple abbreviated new drug applications can compete without the development cost or clinical risk associated with an original NDA. (FDA, 2024a)

What patents protect Salagen and pilocarpine tablets?

Salagen does not have a meaningful live U.S. patent estate that supports premium pricing. The relevant intellectual-property barriers were associated with the original compound, formulation, and regulatory approval period. Those barriers no longer prevent ANDA-based competition.

Patent estate assessment

IP category	Current commercial relevance
Pilocarpine compound patents	Expired or commercially irrelevant
Immediate-release tablet patents	No material blocking protection identified
Method-of-use patents	No known active U.S. protection supporting the core approved uses
Formulation patents	No known current barrier to standard generic tablets
Manufacturing patents	May protect individual suppliers' processes, but do not block ordinary generic entry
Trade dress and brand	Brand differentiation remains, but does not prevent substitution

A generic manufacturer does not need to reproduce Salagen's branding. It must demonstrate pharmaceutical equivalence and bioequivalence to the reference product and comply with FDA manufacturing requirements. Because the product is an immediate-release tablet rather than a complex long-acting formulation, the technical barrier to generic entry is relatively low.

What is the Orange Book status of Salagen?

Salagen's Orange Book position is that of an approved reference listed drug with no commercially meaningful remaining exclusivity. The relevant strategic consequence is that generic manufacturers can compete through the ANDA pathway rather than requiring a full clinical development program.

The absence of an active patent dispute also reduces litigation risk for generic entrants. A company seeking entry would normally assess:

1. Whether Salagen remains the reference listed drug.
2. Whether the target strength has approved generic equivalents.
3. Whether any late-listed patent or exclusivity entry changes the timing.
4. Whether supply constraints create an opportunity despite low unit economics.
5. Whether reimbursement contracts favor a particular generic supplier.

The product's patent risk is therefore low. The principal risks are regulatory execution, manufacturing reliability, and commercial access.

Which companies are challenging Salagen through generic competition?

Generic pilocarpine hydrochloride tablets have been supplied or approved by multiple generic drug manufacturers over time. The competitive field can change as ANDA holders enter, exit, transfer products, or suspend manufacturing.

Known market participants in generic pilocarpine have included large and mid-sized generic manufacturers such as Teva, Hikma, and other ANDA sponsors depending on strength, market period, and distribution channel. A definitive current supplier count requires a contemporaneous FDA approval and commercial-availability review because an approved ANDA does not guarantee active market supply.

The competitive structure has several characteristics:

• The product is a small market relative to high-volume chronic medicines.
• Generic manufacturers compete on supply continuity, wholesaler contracts, and price.
• The 7.5 mg strength is more specialized than the 5 mg strength.
• Limited demand can support only a small number of commercially active suppliers.
• A manufacturing interruption can create temporary pricing power even without patent protection.

How large is the Salagen market?

Salagen addresses a narrow prescription market. Its demand base consists of patients with treatment-related salivary-gland damage, autoimmune disease, and persistent medication-associated dry mouth. The population is medically important but commercially limited.

Demand is constrained by:

• Low diagnosis and treatment rates for xerostomia.
• Adverse effects that reduce persistence.
• Use of nonprescription saliva substitutes and hydration measures.
• Cevimeline substitution in Sjögren's syndrome.
• Physician preference for supportive care.
• Generic substitution and low reimbursement rates.
• The absence of major new approved indications.

The treatment is more likely to be continued by patients who experience clear symptomatic benefit. That persistence supports residual brand demand, particularly among patients who have stabilized on branded tablets or whose pharmacies have changed generic suppliers repeatedly.

What is Salagen's financial trajectory?

Salagen's financial trajectory has three phases.

Launch and protected commercialization

Following FDA approval in 1994, Salagen benefited from branded pricing and limited competition. The product addressed an unmet symptomatic need in a specialized patient population and established recognition among oncology, rheumatology, dentistry, and supportive-care prescribers.

Mature branded sales

Before generic erosion, Salagen generated recurring revenue from chronic use. Sales were supported by long treatment duration in some patients, although tolerability and the limited indication base restricted volume growth.

Generic erosion and residual brand revenue

After generic entry, revenue pressure came from lower generic prices, formulary substitution, pharmacy-level switching, and the absence of new patent protection. Brand sales likely declined materially from their protected-market peak, but public company reports do not provide enough product-level information to calculate a verified annual revenue series.

Financial driver	Effect on Salagen
Generic entry	Strong negative
Patent expiration	Removes pricing protection
Chronic use	Supports recurring volume
Narrow indication base	Limits market expansion
Brand loyalty	Preserves residual branded demand
Generic shortages	Can temporarily support brand or alternative suppliers
New clinical indications	No major approved expansion
Manufacturing complexity	Low to moderate
Reimbursement pressure	High

The most defensible financial conclusion is that Salagen is a low-growth, mature product with declining or flat brand economics and greater value as a steady niche medicine than as a strategic growth asset.

What generic entry risks exist for Salagen?

Generic entry risk is high because the principal barriers to substitution have expired. The risk is not limited to a single future launch. It reflects continuing competition from existing and potential ANDA holders.

Generic launch scenarios

Scenario	Commercial effect
Additional 5 mg generic entrant	Further price compression and share loss
Additional 7.5 mg generic entrant	Lower prices, but potentially limited impact if the market is already concentrated
Generic manufacturing disruption	Temporary shortage and possible brand share recovery
Reimbursement exclusion of brand	Rapid brand-volume decline
Pharmacy substitution restrictions	Slower generic conversion in selected channels
Supplier consolidation	Higher shortage risk and intermittent price increases

For an acquirer, the opportunity would depend on low-cost supply, reliable distribution, and a differentiated access strategy. Patent exclusivity would not be the basis for value.

How does Salagen compare with competing xerostomia treatments?

The main prescription comparison is cevimeline, marketed as Evoxac in the United States. Both products stimulate muscarinic receptors, but they differ in prescribing history, patient response, dosing, and tolerability.

Factor	Salagen	Cevimeline
Active ingredient	Pilocarpine	Cevimeline
Primary use	Xerostomia, including radiation-related dry mouth and Sjögren's syndrome	Primarily Sjögren's-related dry mouth
Form	Immediate-release tablet	Oral capsule
Generic competition	Yes	Yes or market-dependent
Differentiation	Long clinical familiarity and radiation indication	Alternative mechanism profile and dosing
Key commercial issue	Generic substitution and mature demand	Smaller competitive niche

Nonprescription saliva substitutes, mouth moisturizers, water-based products, sugar-free gum, and dental preventive care compete with drug therapy for symptom management. These alternatives reduce the number of patients who require long-term prescription treatment.

What FDA regulatory status does Salagen have?

Salagen is an FDA-approved prescription drug. Its approved uses are established in the original NDA labeling, and no current regulatory exclusivity protects the product from ANDA competition.

The regulatory profile is comparatively simple:

• It is a conventional small-molecule tablet.
• It does not require a biologics license application.
• It does not carry biosimilar risk.
• It does not use a complex delivery system.
• Generic applicants can rely on the reference product through the ANDA pathway.
• Postmarketing obligations are materially lower than for a newly approved specialty drug.

Is there biosimilar risk for Salagen?

No. Salagen is a small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. The relevant competitors are generic pilocarpine products approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

What patent litigation or settlement agreements affect Salagen?

No major current patent litigation or settlement agreement appears to control Salagen's U.S. market access. The product's commercial history is defined by ordinary patent expiry and generic substitution rather than an active Paragraph IV litigation campaign.

A Paragraph IV certification would have been relevant during the period when listed patents remained enforceable. Today, the practical commercial question is whether an ANDA sponsor can maintain approval and supply, not whether it can overcome a live patent barrier.

How strong is the Salagen patent estate?

The patent estate is weak for current commercial purposes.

Patent-strength factor	Assessment
Composition-of-matter protection	Expired
Core indication protection	No material current barrier
Formulation protection	Weak or absent for standard tablets
Manufacturing protection	Supplier-specific and nonblocking
Litigation leverage	Low
Ability to support premium pricing	Low
Freedom-to-operate for standard generic	Generally favorable

The brand's remaining defenses are commercial rather than legal. These include physician familiarity, patient continuity, product availability, and channel relationships.

What is the investment and licensing outlook for Salagen?

Salagen has limited attractiveness as a standalone licensing or acquisition target unless the buyer can improve manufacturing economics or bundle it with a broader specialty-pharmaceutical portfolio.

Potential value drivers include:

• Stable chronic prescription volume.
• A recognized brand in a specialized indication.
• Manufacturing or distribution cost reductions.
• A shortage-resilient supply position.
• Cross-selling into oncology, rheumatology, or dental channels.
• Portfolio synergies with other generic or supportive-care products.

The main valuation constraints are generic substitution, limited market growth, lack of patent protection, modest clinical differentiation, and limited public revenue transparency. A buyer should value Salagen primarily as a cash-flow or portfolio product, not as an exclusivity asset.

Key Takeaways

• Salagen is pilocarpine hydrochloride, an FDA-approved treatment for xerostomia.
• The product has no meaningful remaining U.S. regulatory or patent exclusivity.
• Generic pilocarpine tablets are the principal competitive threat.
• Salagen's market is narrow, mature, and sensitive to reimbursement and supply conditions.
• Eisai's public reporting does not separately disclose reliable Salagen revenue.
• Financial performance is best characterized as residual-brand or mature-generic economics.
• Patent litigation and Paragraph IV activity do not appear to be current market-control factors.
• There is no biosimilar risk because Salagen is a small-molecule drug.
• Commercial value depends on supply reliability, patient persistence, and distribution rather than patent protection.
• Generic launch risk is high, but temporary shortages can create short-term pricing or share opportunities.

FAQs About Salagen Market Dynamics and Exclusivity

Does Salagen still have patent protection?

Salagen does not appear to have a commercially meaningful active U.S. patent estate protecting standard pilocarpine tablets or the core approved indications.

Is pilocarpine available as a generic?

Yes. Generic pilocarpine hydrochloride tablets have been approved and marketed in the United States. Availability can vary by strength, supplier, wholesaler, and time period.

Is Salagen covered by Medicare?

Coverage depends on the Medicare Part D plan, formulary tier, prior authorization rules, and whether the plan prefers a generic pilocarpine product. Brand coverage is generally more restrictive than generic coverage.

Can a generic company launch Salagen without clinical trials?

A generic company can generally use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence rather than repeat Salagen's full clinical development program.

What could increase Salagen's commercial value?

The main potential drivers are a reliable supply position, a temporary generic shortage, stronger distribution in specialty channels, or a portfolio transaction that creates manufacturing and commercial synergies. New patent-based exclusivity is not the likely value driver.

References

1. U.S. Food and Drug Administration. (2021). Salagen (pilocarpine hydrochloride) tablets: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. FDA.

4. Eisai Co., Ltd. (2008). Eisai completes acquisition of MGI PHARMA, Inc. Eisai.

5. National Library of Medicine. (2024). DailyMed: Pilocarpine hydrochloride tablet labeling. U.S. National Library of Medicine.

DrugChatter Q&A for SALAGEN

Salagen coupon?
Salagen medication?
Does medicare cover salagen?